Patent · US Active

Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

US10828299B2 · kind B2 · utility

3Cited by

40References

18Claims

0Family size

Assignee

Kronos Bio, Inc. · US

Inventors

Peter A. Blomgren · Issaquah, US
Kevin S. Currie · North Branford, US
Jeffrey E. Kropf · Branford, US
Seung H. Lee · Sammamish, US
Jennifer R. Lo · Plainsboro, US
Scott A. Mitchell · East Haven, US
Aaron C. Schmitt · Hamden, US
Sundaramoorthi Swaminathan · Burlingame, US
Jin-Ming Xiong · Guilford, US
Jianjun Xu · Bellevue, US
Zhongdong Zhao · Guilford, US

Key dates

Filing date	May 15, 2019
Grant date	Nov 10, 2020
Priority date	—
Expiry date	May 15, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.